A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Trial Profile

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Omadacycline (Primary) ; Linezolid
  • Indications Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms OASIS-2
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 17 Jul 2017 Results published in a Paratek Pharmaceuticals media release.
    • 17 Jul 2017 The results of this study, including the results of the secondary endpoints, will be presented at an upcoming scientific congress, according to a Paratek Pharmaceuticals media release.
    • 17 Jul 2017 Primary endpoint (Clinical success at the post treatment evaluation visit defined as survival after completion of a test article regimen, with resolution of improvement of signs and symptoms of infection) has been met, according to a Paratek Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top